.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, clients along with metastatic gastrointestinal lumps that obtained biomarker-matched therapies based on distributing cyst DNA profiling revealed a higher professional benefit than those getting unrivaled treatment.